Taken together, these findings demonstrate thatthe 5-FU/β-car/NPtreatment can overcome the drug resistance induced by uL3 silencingalso in a 3D tumor growth model, offering a novel therapeutic approachfor treating chemotherapy-resistant CRCs. Here, RPL3 is linked to neoplasm.